Implementation of a diuretic stewardship program in a pediatric cardiovascular intensive care unit to reduce medication expenditures.

PURPOSE The implementation of a diuretic stewardship program in a pediatric cardiovascular intensive care unit (ICU) is described. METHODS This retrospective study compared the use of i.v. chlorothiazide and i.v. ethacrynic acid in pediatric cardiovascular surgery patients before and after implementation of a diuretic stewardship program. All pediatric patients admitted to the pediatric cardiovascular service were included. The cardiovascular surgery service was educated on formal indications for specific diuretic agents, and the diuretic stewardship program was implemented on January 1, 2013. Under the stewardship program, i.v. ethacrynic acid was indicated in patients with a sulfonamide allergy, and i.v. chlorothiazide was considered appropriate in patients receiving maximized i.v. loop diuretic doses. A detailed review of the pharmacy database and medical records was performed for each patient to determine i.v. chlorothiazide and i.v. ethacrynic acid use and expenditures, appropriateness of use, days using a ventilator, and cardiovascular ICU length of stay. RESULTS After implementation of diuretic stewardship, the use of i.v. chlorothiazide decreased by 74% (531 fewer doses) while i.v. ethacrynic acid use decreased by 92% (47 fewer doses), resulting in a total reduction of $91,398 in expenditures on these diuretics over the six-month study period and an estimated annual saving of over $182,000. The median number of days using a ventilator and the length of ICU stay did not differ significantly during the study period. CONCLUSION Implementation of a diuretic stewardship program reduced the use of i.v. chlorothiazide and i.v. ethacrynic acid without adversely affecting clinical outcomes such as ventilator days and length of stay in a pediatric cardiovascular ICU.

[1]  Andrew H. Smith,et al.  Trends in resource utilization associated with the inpatient treatment of neonatal congenital heart disease. , 2014, Congenital heart disease.

[2]  Brian J. Kim,et al.  Comparison of Bumetanide- and Metolazone-Based Diuretic Regimens to Furosemide in Acute Heart Failure , 2013, Journal of cardiovascular pharmacology and therapeutics.

[3]  Adrian F. Hernandez,et al.  Combination of loop diuretics with thiazide-type diuretics in heart failure. , 2010, Journal of the American College of Cardiology.

[4]  M. Elliott,et al.  Paediatric CPB: Bypass in a High Risk Group , 2006, Perfusion.

[5]  J. Tweddell,et al.  Characterizing the inflammatory response to cardiopulmonary bypass in children. , 2006, The Annals of thoracic surgery.

[6]  A. Cohen,et al.  Development of an optimal furosemide infusion strategy in infants with modeling and simulation , 2002, Clinical pharmacology and therapeutics.

[7]  J. den Hartigh,et al.  Continuous intravenous furosemide in haemodynamically unstable children after cardiac surgery , 2001, Intensive Care Medicine.

[8]  E. Bell,et al.  Addition of metolazone to overcome tolerance to furosemide in infants with bronchopulmonary dysplasia. , 1992, The Journal of pediatrics.

[9]  E. Garin A comparison of combinations of diuretics in nephrotic edema. , 1987, American journal of diseases of children.

[10]  W. Arnold,et al.  Efficacy of metolazone and furosemide in children with furosemide-resistant edema. , 1984, Pediatrics.

[11]  S. Cosgrove,et al.  Antimicrobial stewardship. , 2011, Infectious disease clinics of North America.

[12]  ASHP guidelines on medication cost management strategies for hospitals and health systems. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[13]  L. Feld,et al.  Combination of metolazone and furosemide in the treatment of edema in the first month of life. , 1990, Child nephrology and urology.